A Phase I/II Study of Repeat Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-Alpha Antagonists
Latest Information Update: 03 Nov 2021
At a glance
- Drugs TgAAC 94 (Primary)
- Indications Ankylosing spondylitis; Arthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AmpliPhi Biosciences Corporation
- 11 Nov 2008 Phase I/II results were reported at the Meeting of the American College of Rheumatology in Oct 2008. Link to ADNM 801127190 added.
- 12 Jun 2008 Full results were presented during an oral presentation at the Annual European Congress of Rheumatology (EULAR).
- 12 Jun 2008 Status changed from in progress to completed according to Targeted Genetics Corporation.